Clinical Trial Update: A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of CA-4948 in combination with pembrolizumab and stereotactic radiosurgery for melanoma brain metastases is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Melanoma Brain Metastases

Drugs mentioned

• CA-4948
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Florida | Conditions: Melanoma Metastatic in the Brain | Phase 1, Phase 2 | Status: SUSPENDED